<DOC>
	<DOC>NCT01840410</DOC>
	<brief_summary>This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).</brief_summary>
	<brief_title>Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Key Diagnosis of active CNV secondary to any causes with the CNV or its sequelae affecting the fovea; BCVA must be between ≥ 24 and ≤ 83 letters in the study eye; Visual loss in the study eye should mainly be due to the presence of any eligible types of CNV; Key Women of childbearing potential; Active malignancies; History of stroke less than 6 months prior to screening; Uncontrolled systemic inflammation or infection; Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intraocular inflammation; CNV conditions with a high likelihood of spontaneous resolution; History of intravitreal treatment with steroids; History of laser photocoagulation; History of intraocular treatment with any antiangiogenic drugs.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vision Impairment</keyword>
	<keyword>Abnormal growth of blood vessels</keyword>
</DOC>